参考文献/References:
[1] Adler CH,Beach TG,Hentz JG,et al.Low clinical diagnostic accuracy of early vs advanced Parkinson disease Clinicopathologic study[J].Neurology,2014,83(5):406-412.
[2] Shulman LM,Taback RL,Bean J,et al.Comorbidity of the nonmotor symptoms of Parkinson's disease[J].Mov Disord,2001,16(3):507-510.
[3] Ansari KA,Johnson A.Olfactory function in patients with Parkinson's disease[J].J Chronic Dis,1975,28(9):493-497.
[4] Braak H,Del Tredici K,R b U,et al.Staging of brain pathology related to sporadic Parkinson's disease[J].Neurobiol Aging,2002,24(2):197-211.
[5] Siderowf A,Newberg A,Chou KL,et al.99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease[J].Neurology,2005,64(10):1716-1720.
[6] Muller A,Mungersdorf M,Reichmann H,et al.Olfactory function in Parkinsonian syndromes[J].Journal of Clinical Neuroscience,2002,9(5):521-524.
[7] Mesholam RI,Moberg PJ,Mahr RN,et al.Olfaction in neurodegenerative disease:a meta-analysis of olfactory functioning in Alzheimer's and Parkinson's diseases[J].Arch Neurol,1998,55(1):84-90.
[8] Postuma RB,Gagnon JF,Rompr S,et al.Severity of REM atonia loss in idiopathic REM sleep behavior disorder predicts Parkinson disease[J].Neurology,2010,74(3):239-244.
[9] Postuma RB,Iranzo A,Hogl B,et al.Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder:a multicenter study[J].Ann Neurol,2015,77(5):830-839.
[10] Pont-Sunyer C,Iranzo A,Gaig CA,et al.Sleep disorders in parkinsonian and nonparkinsonian LRRK2 mutation carriers[J].PLoS One,2015,10(7):e0132368.
[11] Abbott RD,Petrovitch H,White LR,et al.Frequency of bowel movements and the future risk of Parkinson's disease[J].Neurology,2001,57(3):456-462.
[12] Ueki A,Otsuka M.Life style risks of Parkinson's disease:association between decreased water intake and constipation[J].J Neurol,2004,251(Suppl 7):vII18-vII23.
[13] Lebouvier T,Neunlist M,Bruley Des Varannes S,et al.Colonic biopsies to assess the neuropathology of Parkinson's disease and its relationship with symptoms[J].PLoS One,2010,5(9):e12728.
[14] Drolet RE,Cannon JR,Montero LA.Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology[J].Neurobiol Dis,2009,36(1):96-102.
[15] Brooks DJ.Imaging approaches to parkinson disease[J].Journal of Nuclear Medicine,2010,51(4):596-609.
[16] Orimo S,Suzuki M,Inaba A,et al.I-123-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism:A systematic review and meta-analysis[J].Parkinsonism Relat Disord,2012,18(5):494-500.
[17] Postuma RB,Berg D,Stern M,et al.MDS clinical diagnostic criteria for Parkinson's disease[J].Mov Disord,2015,30(12):1591-1601.
[18] Ulla M,Bonny JM,Ouchchane L,et al.Is R2*a new MRI biomarker for the progression of Parkinson's disease?A longitudinal follow-up[J].PLoS One,2013,8(3):e57904.
[19] Summerfield C,Junqu C,Tolosa E,et al.Structural brain changes in Parkinson disease with dementia:a voxel-based morphometry study[J].Arch Neurol,2005,62(2):281-285.
[20] Becker G,Seufert J,Bogdahn U,et al.Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography[J].Neurology,1995,45(1):182-184.
[21] Berg D,Behnke S,Seppi K,et al.Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease[J].Mov Disord,2013,28(2):216-219.
[22] Berg D,Seppi K,Behnke S,et al.Enlarged substantia nigra hyperechogenicity and risk for parkinson disease a 37-Month 3-Center study of 1847 older persons[J].Arch Neurol,2011,68(7):932-937.
[23] Pilotto A,Yilmaz R,Berg D.Developments in the role of transcranial sonography for the differential diagnosis of parkinsonism[J].Curr Neurol Neurosci Rep,2015,15(7):43.
[24] Malek N,Swallow D,Grosset KA,et al.Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease - a systematic review[J].Acta Neurol Scand,2014,130(2):59-72.
[25] Sako W,Murakami N,Izumi Y,et al.Reduced Alpha-Synuclein in cerebrospinal fluid in synucleinopathies:evidence from a meta-analysis[J].Movement Disorders,2014,29(13):1599-1605.
[26] Stewart T,Liu C,Ginghina C,et al.Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort[J].Am J Pathol,2014,184(4):966-975.
[27] Van Dijk KD,Bidinosti M,Weiss A,et al.Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity[J].European Journal of Neurology,2014,21(3):388-394.
[28] Hall S,Surova Y,hrfelt A,et al.CSF biomarkers and clinical progression of Parkinson disease[J].Neurology,2015,84(1):57-63.
[29] Park MJ,Cheon SM,Bee HR,et al.Elevated levels of alpha-Synuclein oligomer in the cerebrospinal fluid of Drug-Naive patients with parkinson's disease[J].Journal of Clinical Neurology,2011,7(4):215-222.
[30] Tokuda T,Qureshi MM,Ardah MT,et al.Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease[J].Neurology,2010,75(20):1766-1772.
[31] Aasly JO,Johansen KK,Brnstad G,et al.Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers[J].Front Aging Neurosci,2014,6(9):248-255.
[32] Hong Z,Shi M,Chung KA,et al.DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease[J].Brain,2010,133(Pt 3):713-726.
[33] Shi M,Zabetian CP,Hancock AM,et al.Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease[J].Neurosci Lett,2010,480(1):78-82.
[34] Lin XM,Cook TJ,Zabetian CP,et al.DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease[J].Sci Rep,2012,2(12):954-963.
[35] Shi M,Furay AR,Sossi V,et al.DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function[J].Neurobiol Aging,2012,33(4):836.e5-836.e7.
[36] Montine TJ,Shi M,Quinn JF,et al.CSF Aβ(42)and tau in parkinson's disease with cognitive impairment[J].Mov Disord,2010,25(15):2682-2685.
[37] Alves G,Lange J,Blennow K,et al.CSF A beta(42)predicts early-onset dementia in Parkinson disease[J].Neurology,2014,82(20):1784-1790.
[38] Aasly JO,Shi M,Sossi V,et al.Cerebrospinal fluid amyloid beta and tau in LRRK2 mutation carriers[J].Neurology,2012,78(1):55-61.
[39] Klein C,Schlossmacher MG.Parkinson disease,10 years after its genetic revolution:multiple clues to a complex disorder[J].Neurology,2007,69(22):2093-2104.
[40] Healy DG,Falchi M,O'sullivan SS,et al.Phenotype,genotype,and worldwide genetic penetrance of LRRK2-associated Parkinson's disease:a case-control study[J].The Lancet Neurology,2008,7(7):583-590.
[41] Oosterveld LP,Allen J,Ng EY,et al.Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants[J].Neurology,2015,85(12):1039-1042.
[42] Sidransky E,Nalls MA,Aasly JO,et al.Multicenter analysis of glucocerebrosidase mutations in parkinson's disease[J].N Engl J Med,2009,361(17):1651-1661.
[43] Winder-Rhodes SE,Evans JR,Ban M,et al.Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort[J].Brain,2013,136(Pt 2):392-399.
[44] Beavan M,Mcneill A,Proukakis CA,et al.Evolution of prodromal clinical markers of parkinson disease in a GBA Mutation-Positive cohort[J].JAMA Neurol,2015,72(2):201-208.